Chemed Corp

Valuation Analysis

About the Company

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Chemed Corp Stock at a Glance

Chemed Corp (CHE) is currently trading at $419.31 with a market capitalization of $5.6B. The trailing P/E ratio stands at 22.89x, with a forward P/E of 15.58x. The 52-week range spans from $365.21 to $562.77; the current price is 25.5% below the yearly high. Year-over-year revenue growth stands at +1.6%. The net profit margin stands at 10.22%.

💰 Dividend

Chemed Corp pays an annual dividend of $2.40 per share, representing a yield of 0.57%. The payout ratio stands at 12.55%.

📊 Analyst Rating

4 analysts rate Chemed Corp (CHE) on consensus: Buy. The average price target is $446.50, implying +6.48% from the current price. Analyst price targets range from $400.00 to $500.00.

Chemed Corp: The Investment Case in Detail

Chemed Corp (CHE) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Return on equity of 25.6% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

The Bear Case

Revenue growth has slowed to just 1.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

What to Watch Next

• The forward P/E of 15.58x is meaningfully below the trailing 22.89x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (5.64%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Chemed Corp?

Compare top-rated brokers — low fees, trusted providers, fully regulated.